Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Kielce – page 14

187 clinical trials in Kielce, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Kielce at a glance
187
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

187 trials in Kielce

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Generalised tonic-clonic seizure

Not recruiting

Study on the Effectiveness and Safety of Cenobamate for Patients Aged 12 and Older with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cenobamate
  • Sponsor:Sk Life Science Inc.

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Multiple sclerosis relapse

Not recruiting

Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Malignant melanoma

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Mantle cell lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Hormone-refractory prostate cancer

Not recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Novartis Pharma AG

Endometrial cancer

Not recruiting

Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Fallopian tube cancer+1

Not recruiting

Study of Pembrolizumab, MK-4830, and Chemotherapy for Patients with High-Grade Serous Ovarian Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Kielce

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, breast cancer, and lymphoma treatments. Studies evaluate novel drug combinations and targeted therapies for improved patient outcomes.

  • Blood cancers and solid tumors
  • Targeted therapy approaches
  • Combination treatment strategies

Advanced research includes studies on prostate cancer and neuroendocrine tumors using cutting-edge therapeutic approaches.

02 Neurological Disorders

Groundbreaking research in multiple sclerosis and Alzheimer's disease. Trials evaluate new treatments for both relapsing forms of MS and psychosis associated with Alzheimer's.

  • Disease-modifying therapies
  • Neurodegeneration treatments
  • Symptom management

Focus on developing innovative therapeutic solutions for complex neurological conditions.

03 Cardiovascular and Metabolic Studies

Comprehensive research addressing hypertension, cardiovascular disease, and metabolic disorders. Studies investigate preventive approaches and novel treatment combinations.

  • Heart failure prevention
  • Blood pressure management
  • Metabolic health

Innovative trials exploring new therapeutic strategies for cardiovascular risk reduction.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.